MDXH Stock Overview
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MDxHealth SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.26 |
| 52 Week High | US$4.64 |
| 52 Week Low | US$1.55 |
| Beta | -391108.3 |
| 1 Month Change | 20.21% |
| 3 Month Change | -14.56% |
| 1 Year Change | -40.84% |
| 3 Year Change | -78.27% |
| 5 Year Change | -79.45% |
| Change since IPO | -97.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDXH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.8% | -3.6% | -2.4% |
| 1Y | -40.8% | -2.6% | 23.4% |
Return vs Industry: MDXH underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: MDXH underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| MDXH volatility | |
|---|---|
| MDXH Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDXH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDXH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 300 | Mike McGarrity | mdxhealth.com |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment.
MDxHealth SA Fundamentals Summary
| MDXH fundamental statistics | |
|---|---|
| Market cap | US$106.87m |
| Earnings (TTM) | -US$41.95m |
| Revenue (TTM) | US$84.71m |
1.3x
P/S Ratio-2.5x
P/E RatioIs MDXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXH income statement (TTM) | |
|---|---|
| Revenue | US$84.71m |
| Cost of Revenue | US$32.41m |
| Gross Profit | US$52.30m |
| Other Expenses | US$94.24m |
| Earnings | -US$41.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 61.74% |
| Net Profit Margin | -49.52% |
| Debt/Equity Ratio | 302.2% |
How did MDXH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 21:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MDxHealth SA is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ruzic-Gauthier | Berenberg |
| Mark Massaro | BTIG |
| Roderick Verhelst | Degroof Petercam |